The $100 million disease team round applications are under discussion currently at today's meeting of the governing board of the California stem cell agency.
CIRM Chairman Jonathan Thomas outlined the appeal process prior to the discussion and cautioned rejected applicants in the audience that the board is not the first avenue of appeals.
The board has revised its appeal process in the last year to discourage appeals directly to the board. Over the last couple of years, the appeals have often involved emotional presentations by patient advocates seeking to support applications.
Nonetheless, under state law, any person has a right to address the board on any subject.
No comments:
Post a Comment